P-Anisic Acid

P-Anisic Acid

SCHEMBL6590201

C1CC2CC1O2.COc1ccc(C(=O)O)cc1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.67
CA2 P00918 3/20 0.67
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
XDH P47989 1/20 0.49
KDM4E B2RXH2 1/20 0.49
CES2 O00748 2/20 0.48
CES1 P23141 2/20 0.48
CHEK1 O14757 1/20 0.48
RXRA P19793 1/20 0.47
CNR2 P34972 1/20 0.47
GAA P10253 1/20 0.47
NR4A2 P43354 1/20 0.46
PARP1 P09874 1/20 0.46
PARP10 Q53GL7 1/20 0.46
PARP2 Q9UGN5 1/20 0.46
PARP4 Q9UKK3 1/20 0.46
PLA2G4B P0C869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Anisic Acid SCHEMBL6586036 0.98 CA1 (0.65) CA1CA2NPC1RAB9APOLB
P-Anisic Acid SCHEMBL29145864 0.88 CA1 (0.74) CA1CA2NPC1RAB9APOLB
SCHEMBL7447320 0.87 NPC1 (0.49) CA1CA2NPC1RAB9APOLB
P-Anisic Acid SCHEMBL27396257 0.83 CA1 (0.71) CA1CA2NPC1RAB9APOLB
P-Anisic Acid SCHEMBL43335 0.82 CA1 (1.00) CA1CA2NPC1RAB9APOLB
P-Anisic Acid SCHEMBL1157044 0.82 CA1 (1.00) CA1CA2NPC1RAB9APOLB
P-Anisic Acid SCHEMBL846287 0.80 CA1 (0.95) CA1CA2NPC1RAB9APOLB
P-Anisic Acid SCHEMBL2130101 0.80 CA1 (0.95) CA1CA2NPC1RAB9APOLB
P-Anisic Acid SCHEMBL15548197 0.80 CA1 (0.95) CA1CA2NPC1RAB9APOLB
P-Anisic Acid SCHEMBL1043957 0.80 CA1 (0.95) CA1CA2NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105646399-B An unusually sweet smell orchid acid derivative and the small cyclammonium condensation gained benzamides people's PDE4B inhibitor of saturation 重庆医科大学 2019-03-08 CN disclosed
US-20040043999-A1 Phthalazine derivatives as phosphodiesterase 4-inhibitors ZAMBON GROUP S.P.A 2004-03-04 US disclosed
EP-1042300-B1 PHTHALAZINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON SPA (IT) 2004-02-11 EP disclosed
US-6589951-B1 N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. ZAMBON GROUP S.P.A. (IT) 2003-07-08 US disclosed
US-6498160-B2 FOR THERAPY OF EMPHYSEMA, CHRONIC BRONCHITIS, ASTHMA AND ALLERGIC RHINITIS ZAMBON GROUP S.P.A. (IT) 2002-12-24 US disclosed
CN-1090614-C N- (aroyl) glycine hydroxamic acid derivatives and related compounds PFIZER (US) 2002-09-11 CN disclosed
US-20020058662-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors ZAMBON GROUP S.P.A. (IT) 2002-05-16 US disclosed
US-6340684-B1 TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, ALLERGIC RHINITIS ZAMBON GROUP S.P.A. (IT) 2002-01-22 US disclosed
EP-1098886-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.p.A. (IT) 2001-05-16 EP disclosed
EP-1042300-A1 PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.p.A. (IT) 2000-10-11 EP disclosed
WO-2000005219-A1 PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 2000-02-03 WO disclosed
WO-1999032456-A1 PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS ZAMBON GROUP S.P.A. (IT) 1999-07-01 WO disclosed
CN-1192201-A N- (aroyl) glycine hydroxamic acid derivatives and related compounds PFIZER (US) 1998-09-02 CN disclosed
EP-0607373-B1 TRISUBSTITUTED PHENYL DERIVATIVES AS SELECTIVE PHOSPHODIESTERASE IV INHIBITORS CELLTECH THERAPEUTICS LTD (GB) 1997-03-19 EP disclosed
US-5340827-A Phenylcarboxamide compounds which have useful pharmaceutical activity CELLTECH, LIMITED (GB) 1994-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058662-A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 CA1 3917/4885CA2 903/4885NPC1 3401/4885
US-20040043999-A1 Phthalazine derivatives as phosphodiesterase 4-inhibitors PDE5A, PDE3B, PDE3A CA1 1939/4885CA2 468/4885NPC1 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.